Professor Clifford Leen
Lead clinician for clinical research in the Regional Infectious Disease Unit at the Western General Hospital, Edinburgh.
My research interests include the evaluation of antiviral drugs and drug resistance, the management of opportunistic infections and the evaluation of anti-infectives. I am currently researching new anti-bacterial and anti-viral agents .
Selected publications
Prognostic value of vitamin D level for all-cause mortality, and association with inflammatory markers, in HIV-infected persons. Shepherd L, Souberbielle JC, Bastard JP, Fellahi S, Capeau J, Reekie J, Reiss P, Blaxhult A, Bickel M, Leen C, Kirk O, Lundgren JD, Mocroft A, Viard JP; On behalf of EuroSIDA in EuroCOORD. J Infect Dis. 2014 Feb 3.
HLA B*5701 status, disease progression, and response to antiretroviral therapy. UK Collaborative HIV Cohort Study Steering Committee. AIDS. 2013 Oct 23;27(16):2587-92.
Neurocognitive function in HIV infected patients on antiretroviral therapy.Winston A, Arenas-Pinto A, Stöhr W, Fisher M, Orkin CM, Aderogba K, De Burgh-Thomas A, O'Farrell N, Lacey CJ, Leen C, Dunn D, Paton NI; PIVOT Trial Team. PLoS One. 2013 Apr 30;8(4):e61949.
Failure to achieve a CD4+ cell count response on combination antiretroviral therapy despite consistent viral load suppression. O'Connor JL, Smith CJ, Lampe FC, Hill T, Gompels M, Hay P, Chadwick D, Fisher M, Ainsworth J, Gilson R, Mackie N, Anderson J, Orkin C, Nelson M, Kegg S, Leen C, Palfreeman A, Post F, Johnson M, Sabin CA, Phillips AN. AIDS. 2013 Dec 11.
British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012.Writing Group, Williams I, Churchill D, Anderson J, Boffito M, Bower M, Cairns G, Cwynarski K, Edwards S, Fidler S, Fisher M, Freedman A, Geretti AM, Gilleece Y, Horne R, Johnson M, Khoo S, Leen C, Marshall N, Nelson M, Orkin C, Paton N, Phillips A, Post F, Pozniak A, Sabin C, Trevelion R, Ustianowski A, Walsh J, Waters L, Wilkins E, Winston A, Youle M. HIV Med. 2014 Jan;15 Suppl 1:1-85. doi: 10.1111/hiv.12119.
The effects of age on associations between markers of HIV progression and markers of metabolic function including albumin, haemoglobin and lipid concentrations. Samuel M, Jose S, Winston A, Nelson M, Johnson M, Chadwick D, Fisher M, Leen C, Gompels M, Gilson R, Post F, Hay P, Sabin C; UK Collaborative HIV Cohort Study (UK CHIC). HIV Med. 2013 Nov 19. doi: 10.1111/hiv.12103.
Winston A, Jose S, Gibbons S, Back D, Stohr W, Post F, Fisher M, Gazzard B, Nelson M, Gilson R, Orkin C, Johnson M, Palfreeman A, Chadwick D, Leen C, Schwenk A, Anderson J, Gompels M, Dunn D, Khoo S, Sabin C; UK Collaborative HIV Cohort Study. Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoring. J Antimicrob Chemother. 2013 Jun;68(6):1354-9. doi: 10.1093
Waters L, Bansi L, Asboe D, Pozniak A, Smit E, Orkin C, Fearnhill E, Dunn D, Phillips A; UK CHIC Study; UK HIV Drug Resistance Database. Second-line protease inhibitor-based antiretroviral therapy after nonnucleoside reverse transcriptase inhibitor failure: the effect of a nucleoside backbone. Antivir Ther. 2013;18(3):213-9. doi: 10.3851
Bansi L. Gazzard B. Post F. Phillips A. Johnson M. Hill T. Gilson R. Leen C. Walsh J. Fisher M. Sabin C. UK Collaborative HIV Cohort Study. Biomarkers to monitor safety in people on art and risk of mortality. Journal of Acquired Immune Deficiency Syndromes: JAIDS. 60(1):51-8, 2012 May 1.
Ramachandran P. Fraser A. Agarwal K. Austin A. Brown A. Foster GR. Fox R. Hayes PC. Leen C. Mills PR. Mutimer DJ. Ryder SD. Dillon JF. UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients. Alimentary Pharmacology & Therapeutics. 35(6):647-62, 2012 Mar.